TannerLAC provides pharmaceutical, biotech, and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets. Under the license agreement, Tanner will register, commercialize, and promote Visbiome® initially in Mexico, with plans to expand to other Latin American countries.

“Years ago, I witnessed firsthand how Visbiome® transformed the lives of two people close to me,” said Carolina Cortez, EVP of TannerLAC. “Today, we are thrilled to partner with ExeGi and begin our journey in Mexico. We are confident that Visbiome® will be a valuable addition to our portfolio and will enable patients in Mexico to finally access this potent probiotic that has proven to support individuals with various digestive conditions.”

“We are excited to collaborate with Tanner to make Visbiome® accessible to patients in Mexico,” said Marc Tewey, ExeGi’s CEO. “The Tanner team is ideally suited to manage the regulatory and commercial requirements for distributing our product to our Mexican neighbors.”

To learn more about Visbiome®, please visit www.visbiome.com.

About ExeGi Pharma

ExeGi Pharma LLC is a biotechnology company focused on developing and commercializing live biotherapeutic and probiotic medicines. Our purpose is to formulate the most effective probiotics and live biotherapeutics to provide relief from serious conditions so people, and their pets, may live healthier lives. ExeGi is headquartered in Rockville, MD. For more information, please visit www.exegipharma.com.

About Tanner Pharma Group Tanner Pharma Group is a specialist pharmaceutical partner focused on improving global access to medicines. By partnering with Tanner Pharma, companies can focus on their primary markets while ensuring that patients and clinicians in international markets can also benefit from using their products. Tanner Pharma has a global reach and provides international commercialization and patient access through product registration and licensing, managed and global access programs and clinical trial solutions. For more information, please visit www.tannerpharma.com.

For further information, please contact:

Hepilor® is a medical device, indicated for the protection of the digestive system mucosa. Hepilor® adheres to the damaged, ulcerated and inflamed mucosa and works as a mucosal defense agent to protect and promote natural healing of the gastrointestinal mucosal lining and relieve dyspeptic symptoms. This line of products is available in both liquid (200 ml) and capsule (20 capsules of 37.5mg) formats, as well as mouthwash (150ml) and as a single-dose stick-pack.

TannerLAC provides pharmaceutical, biotech and healthcare companies with a single-point partner for the commercialization of their products in challenging international markets. AFI, through the support of their partner PB Pharma Group, engaged TannerLAC to bring this mucosal defense agent to gastric patients in Latin America. Under the license agreement, TannerLAC will be responsible for the registration, commercialization and promotion of Hepilor® in Latin American countries. The official launch of the product in this region, including Mexico and most countries throughout Central and South America, is expected for 2024.

Carolina Cortez, EVP of TannerLAC, commented “Given the increasing number of patients developing gastrointestinal disorders worldwide, we were very pleased when we were introduced to Hepilor® by PB Pharma Group. This product has different formulations that act directly on digestive system mucosa and can treat a variety of diseases. We have heard touching testimonies of patients who have been positively impacted with the use of the product. Therefore, we are eager to work with AFI’s innovative team to bring Hepilor® to Latin America and help many patients in need.”

Miro Costantini and Lorenzo Monticelli, Owners & CEO’s of AFI, commented “It has been always our dream to develop innovative and breakthrough products, sharing our experience in the research & developing with a partner with huge knowledge and amazing experience in international markets. With Tanner we have found not only this but something more, a wonderful and extremely professional team. It will be exciting to work with them sharing the same goals.”

To learn more about Hepilor® visit http://www.aziendafarmaceuticaitaliana.it/

About Azienda Farmaceutica Italiana

Azienda Farmaceutica Italiana was founded in 2014. Since its foundation, the experience of the professional managers, gained in multinational pharmaceutical companies, has allowed for the development of a flexible organization that is adapted to the needs of an increasingly complex and ever-changing market. By orienting the core business towards pharmaceutical innovation, and presenting new generation medical devices and drugs to the market, AFI presents itself as a true protagonist of the national and European pharmaceutical market. The mission of AFI is to find new therapeutic solutions and new treatment possibilities to improve the quality of life of patients. For more information, please visit www.aziendafarmaceuticaitaliana.it.

About Tanner Pharma Group

Tanner Pharma Group is a specialist pharmaceutical partner focused on improving global access to medicines. By partnering with Tanner Pharma, companies can focus on their primary markets while ensuring that patients and clinicians in international markets can also benefit from using their products. Tanner Pharma has a global reach and provides international commercialization and patient access through product registration and licensing, managed and global access programs and clinical trial solutions. For more information, please visit www.tannerpharma.com.

About PB Pharma Group

PB Pharma Group is an enterprise business consulting group founded in 2006 that supports Italian and foreign companies with the import and export of pharmaceuticals and nutraceuticals. In particular, the company’s core business consists of establishing strong partnerships with drug wholesalers and manufacturers who are seeking new foreign market development. PB Pharma Group’s network of relationships in Italy and foreign countries, and its consolidated presence in the market, allows the company to serve as a competent and competitive partner in the complex pharmaceutical market. The business board consists of managers and professionals coming from different experiences (national and international) and with a deep knowledge of the market of reference. For more information, please visit www.pbpharmagroup.com.

For further information, please contact:

Under the license agreement, TannerLAC will be responsible for product registrations, sales, and marketing activities in the Latin American region. First approvals are expected within the second half of 2021.

Carolina Cortez, EVP of TannerLAC, commented, “We are thrilled to partner with Epimune to be able to bring this revolutionary technology to Latin America to help immunodeficient patients have access to the i.Mune TBNK in-vitro diagnostic test that will facilitate early screening and monitoring which will help physicians make the best decisions when treating them.”

“We are very pleased to work with TannerLAC as a highly committed partner in making our i.Mune TBNK product widely available in Latin America,” said Uwe Staub, PhD, CEO of Epimune GmbH. “This partnership provides quick and professional access to the Latin American market which we consider very important for our product. We are looking forward to working closely with the TannerLAC team over the coming months. Together we will offer solutions to this market over the years ahead.”

About Epimune GmbH

Epimune is a molecular diagnostic company that develops and commercializes in vitro diagnostic (IVD) tests for molecular (i.e. epigenetic) immune cell quantification. The products are based on real-time PCR technology and allow accurate quantification of different immune cell subtypes from a drop of fresh, frozen or dried blood. Epimune’s first IVD product – i.Mune TBNK – allows quantification of CD3+, CD4+, CD8+ T-, B- and NK lymphocytes from as little as 40 μl of fresh blood or a dried blood spot (DBS). Epimune targets applications, where fresh blood samples are difficult or impossible to obtain. Lymphocyte enumeration can be used for follow-up and diagnostic evaluation of primary immunodeficiency, monitoring of HIV-positive patients, immune monitoring following immunosuppressive therapy for transplantation, autoimmunity and other immunological conditions, assessment of immune reconstitution post hematopoietic stem cell transplantation, early screening of gross quantitative anomalies in lymphocyte subsets in infections and malignancies and absolute quantification of circulating B cells for diagnosis of chronic lymphocytic leukemia (CLL) patients.

About Tanner Pharma Group

For over 18 years, Tanner Pharma Group has partnered with companies to provide turn-key solutions to increase access to medicines and other medical technology around the world. By partnering with Tanner Pharma Group, companies are able to focus on their primary markets while ensuring that patients and clinicians in international markets can receive their products through a strictly controlled channel. Tanner Pharma Group is headquartered in the United States with offices in the United Kingdom, Switzerland, Ireland and Brazil. Tanner Pharma Group has a global reach and provides international commercialization and patient access through licensing, managed access programs, global access programs and clinical trial services. For more information, please visit www.tannerpharma.com.

Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner Pharma Group.

Little Wilson, or ‘Wilsito’ – as his parents call him – is a 20-month-old boy with a rare form of muscle condition called centronuclear myopathy (CNM). He has lived almost all his life at the hospital, because in Ecuador – the country he was born – the healthcare system cannot provide for home-equipment needed for Wilson’s survival. This includes a set of two ventilators, suctioning machine, cough assist, oxygen concentrator to count a few.

Desperate to bring Wilson home, his family reached out to Jen – also original from Ecuador -from ZNM – Zusammen Stark! e.V., a German association that helps families with centronuclear myopathies. She connected with Alison from the Joshua Frase Foundation, the US association for centronuclear myopathies and from then on, all the magic started!

Alison has been such blessing for Wilson and his family. First, she found two families willing to donate all the necessary equipment for Wilson, as their own sons sadly passed away recently. Then, she connected with another CNM-family, willing to pack all the equipment to be shipped. And not only that, she managed to send all the equipment to Ecuador with the guidance and financial support of Tanner Pharma Group, a global specialist pharmaceutical services provider based on the US.

Meanwhile in Ecuador, Jen’s sister-law, Maricarmen, made all respective procedures to legally nationalize all equipment at customs. “It was definitely not an easy task, however, we as a team succeeded to provide Wilsito with the life-saving equipment so much needed to send him home with his family and friends” said Maricarmen.

The equipment has been tested by Wilson under medical supervision and now the dream to take Wilson home became true! “Wilsito is finally home and our hearts are overwhelmed with joy and gratitude for all these wonderful people that help us in our journey” said Andreina, Wilson’s mother and added “Wilsito will finally learn, play and cuddle with his family at home, where he belongs!”. The joy brought to Wilson’s family is beyond measure.

“We thank wholeheartedly each and every one who made this dream come true. It is fascinated, what can be achieved, if a bunch of people work together for a common goal” said Jen, while Alison added “this story is indeed one powerful demonstration of teamwork and perseverance and will keep motivating us to work for these beautiful children in the future”.

Now, the next challenge is just around the corner: For Wilsito to stay at home the family needs support to buy consumables (circuits, filters, canules, just to mentioned a few) for this medical care, as well as to pay for home visits for physiotherapists and pediatricians. ZNM – Zusammen Stark! e. V and Joshua Frase Foundation already received from generous individual donors around the globe about 1500 € and consumables enough for his first six months at home. Please help us with a donation to keep Wilsito at home with his family.

Thank you so much! Only with your support, we are #TogetherEvenStronger and #AlwaysfortheChildren.

About Centronuclear Myopathies

Centronuclear myopathies are very rare muscle diseases. The most affected children with centronuclear myopathies cannot walk; they need a feeding tube and a ventilator to support their breathing. This, however, does not stop their will to learn, play and discover the world, as other children in their age.

About ZNM – Zusammen Stark! e.V.

(CNM – Together Strong!) is a self-help association for myotubular myopathy and other centronuclear myopathies (CNM = ZNM). We represent 165 individuals from 63 families with a CNM in Germany, the Netherlands and Austria. As a self-help organization our main goal is to connect those affected and their families, and to support each other in our daily lives. This is mainly done by our yearly family conference, webinars and our closed Facebook support group. We also actively invest on research to find a treatment for these conditions. For more information please visit https://www.znm-zusammenstark.org/en

About The Joshua Frase Foundation

(JFF) is a 501C3 non-profit organization that was founded in 1996; a year after Paul and Alison’s son was born with an ultra rare and fatal neuromuscular disorder.  Without hesitation, the foundation began funding cutting-edge research in the area of regenerative medicine, gene therapy and genetics since 1997.  JFF’s mission is twofold: To find a cure or treatment for centronuclear and myotubular myopathies and to support families whose lives are affected by these disorders. Not only has JFF been able to fund groundbreaking science, pioneering into a curative treatment that has the potential to transform neuromuscular research; it has also built an international community of children and their parents. For more information, please visit http://www.joshuafrase.org.

About Tanner Pharma Group

Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, USA with offices in Europe and Latin America. The company has developed a portfolio of service offerings focused on improving the global access to medicines. Since 2002, Tanner Pharma Group has partnered with biopharmaceutical companies and non-profit organizations to provide turn-key solutions to increase patient access to medicines around the world. For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

MILAN, ITALY and CHARLOTTE, USA – Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries.

The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan).

“We are pleased to be working with Tanner Pharma Group to deliver this innovative treatment to patients with a serious unmet medical need. We believe expanding the distribution of Oxervate will dramatically improve the lives of many now living with this highly debilitating disease” said Eriona Gjinukaj, Chief Operating Officer of Dompé.

Rob Keel, Global Head of Managed Access Programs at Tanner Pharma Group, commented, “We are pleased to partner with Dompé on this important initiative. Our unique delivery model will allow us to effectively and efficiently support physicians and patients worldwide to gain access to Oxervate on a named patient basis in countries where no alternatives are commercially available.”

Healthcare professionals in countries outside of the United States, Canada, Italy, China, and CIS countries can obtain details about obtaining Oxervate by contacting Tanner at:

About Neurotrophic Keratitis

Neurotrophic keratitis is a rare, degenerative disease of the cornea, which results in persistent epithelial defects, corneal ulcers, melting, perforation and vision loss. It is an orphan disease with an estimated prevalence of less than 5/10,000 individuals, and previous treatment options had been limited to symptomatic treatments which do not target the underlying disease pathology.

About Oxervate:

Oxervate (cenegermin) is the first application of a human nerve growth factor as drug or treatment and is the first-ever topical biologic medication approved in ophthalmology for a rare disease of the eye. Oxervate is approved in Europe and the United States, Switzerland, Israel, Canada and Australia. The agreement allows Tanner Pharma Group to provide access to Oxervate for patients in countries where there is presently no therapeutic alternative.

About Dompé:

Dompé is an Italian bio-pharmaceutical company that focuses on innovation, with a long tradition in the field of personal wellness that goes hand in hand with a commitment to research and development to meet the unsatisfied therapeutic needs of patients. Dompé, based in Milan with a presence in the United States (in Boston and San Francisco), focuses specifically in the field of rare diseases within its biotechnology unit, in recent years moving into the area of ophthalmology. For more information, visit www.dompe.com.

About Tanner Pharma Group:

Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, USA with offices in Europe and Latin America. The company has developed a portfolio of service offerings focused on improving the global access to medicines. Through its Managed Access Programs division, Tanner supports manufacturers by providing ethical, controlled and compliant access to their innovative medicines in countries where they are not commercially accessible. For more information, visit www.tannerpharma.com.

A named patient program, also known as an early or expanded access program, is a mechanism through which physicians can legally and ethically prescribe investigational or approved drugs for patients prior to their commercial availability. Under the terms of the agreement, Tanner will be the exclusive supplier of Apealea to health care providers outside of the U.S. on a named patient basis in countries where Apealea is not yet commercially available.

“We are excited to partner with Tanner to ensure patients outside of the U.S. who have no therapeutic alternatives are able to access to Apealea through a named patient program,” said Alex Kim, chief executive officer of Elevar Therapeutics.

“We are pleased to give hope to patients around the world through our partnership with Elevar for Apealea,” said Banks Bourne, chairman and founder of Tanner Pharma Group. “The named patient program will help ensure that patients who have no alternative therapeutic options for their disease receive access to Apealea in a manner that is reliable, responsible, ethical and in accordance with all local regulatory requirements.”

“We are delighted to see that patients and doctors in European countries outside the Nordic region, where Oasmia has already launched Apealea, will now get early access,” said Francois Martelet, CEO of Oasmia. “Elevar partnering with Tanner Pharma for a named patient program is a valid means to achieve that access outside of the US. We continue to support Elevar in the identification and selection of regional commercialization partners worldwide and will update our progress in due course.”

About Apealea® (paclitaxel micellar)
Apealea® is a patented, water-soluble, intravenously injectable formulation of paclitaxel, developed using Oasmia’s proprietary technology platform – XR17 – which facilitates the formulation of paclitaxel without Cremophor. Paclitaxel is a well-known chemotherapy agent used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancers. Apealea® has been authorized for marketing by the European Commission for use in combination with carboplatin in adult patients with a first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. It is Europe’s first Cremophor-free formulation of paclitaxel approved for use in ovarian cancer.

About Elevar Therapeutics
Elevar Therapeutics (formerly LSK BioPharma) is a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer. Elevar Therapeutics’ lead proprietary drug candidates include rivoceranib (apatinib), a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors, and Apealea® (paclitaxel micellar), a non-Cremophor based formulation of paclitaxel. Apealea received market authorization by the European Commission in November of 2018, making it Europe’s first Cremophor-free formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has locations in Utah, California and South Korea, and additional information is available at www.elevartherapeutics.com.

About Tanner Pharma Group
Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, USA with offices in Europe and Latin America. Over 18 years, Tanner has developed a portfolio of service offerings focused on improving the global access to medicines. Through its Managed Access Programs division, Tanner supports manufacturers by providing ethical, controlled and compliant access to their innovative medicines in countries where they are not commercially accessible. For more information, visit http://www.tannerpharma.com.

Elevar Media Contact:
Elixir Health Public Relations
Lindsay Rocco
(862) 596-1304
lrocco@elixirhealthpr.com

Tanner Pharma Group Media Contact:
CBQ Communications
Christine Quern
617.650.8497
cq@christinequern.com

SOURCE: Elevar Therapeutics

May 12, 2020

For Immediate Release

Contact:

Telephone: 704-552-8407

Email: versacloz@tannerpharma.com

CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a distributor of Versacloz in areas outside of the United States where the product is not yet registered (excluding Australia, Ireland, and United Kingdom). Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.

The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turn- key global access solutions for the distribution of products from markets of supply to markets of demand.

Maryori Alvarenga, Managing Director of US and Global Director for TannerGAP, commented, “Tanner is looking forward to helping patients in need with the supply of Versacloz otherwise not available in their Market.”

Jeff Douglas, Managing Director of Tasman Pharma Inc., added, “We are looking forward to our partnership with Tanner which will help more patients in need gain access to our cost-effective, evidence-based therapeutic options”.

To obtain additional details about Global Access Programs, please contact a Tanner Pharma representative at +1 704 552 8408 or email general@tannerpharma.com. For Versacloz product related enquiries, please email versacloz@tannerpharma.com.

About Versacloz:

Versacloz is an antipsychotic medicine that is used to treat schizophrenia after other treatments have failed. This medicine is available only from a certified pharmacy under a special program. Versacloz is also used to reduce the risk of suicidal behavior in people with schizophrenia or similar disorders.

About Tasman Pharma Inc.:

Tasman Pharma Inc. is part of the Douglas Pharmaceuticals group of companies and focuses on delivering cost effective medicines in the US.

About Tanner Pharma Group

For over 17 years, Tanner Pharma Group has partnered with biopharmaceutical companies to provide turn-key solutions to increase patient access to medicines around the world. By partnering with Tanner Pharma, biotech and pharma companies are able to focus on their primary markets while ensuring that patients in international markets of need are receiving their products through a strictly controlled channel.

Headquartered in the U.S., Tanner has a global reach and provides international commercialization through licensing, managed access programs, global access programs and clinical trial procurement.

For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

XIAPEX®, also owned by Endo, was previously marketed by Swedish Orphan Biovitrum AB (Sobi) in the EU and other European countries until the withdrawal of its EU Marketing Authorization on March 1, 2020. The decision to withdraw was not based on safety or efficacy concerns. The agreement names Tanner Pharma Group as the exclusive provider of the U.S. product XIAFLEX in markets previously served by Sobi, to address the unmet need for collagenase injection therapy.

Banks Bourne, Chairman and Founder of Tanner Pharma Group, commented, “We are pleased to support physicians who were previously using XIAPEX by providing an ethical and compliant route to an alternative product. Our unique delivery model will minimize the disruption caused by this withdrawal and will ensure that collagenase injection therapy remains an option for European healthcare professionals and patients.”

Healthcare professionals can obtain details about the XIAFLEX Named Patient Program by contacting Tanner at:

Telephone +44 (0) 2039 408111
Email xiaflex@tannerpharma.com

About XIAFLEX:

Initially approved by the US FDA in 2010, XIAFLEX is a combination of bacterial collagenases indicated for the treatment of Dupuytren’s contracture in adult patients with a palpable cord and for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. XIAFLEX represents an important nonsurgical treatment option for these patients, which works through enzymatic disruption of collagen cords and plaques.

About Endo:

Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

CHARLOTTE, N.C. – Key directors from Tanner Pharma Group (“Tanner Pharma”), a Charlotte-based global pharmaceutical services company, will attend several international healthcare conferences throughout the upcoming months of March and April. The team will join other global executives for the following events:

 Clinical Trial Supply Europe | March 13th – 14th | Milan, Italy
 DCAT Week | March 18th – 21st | New York City, New York
 PharmagoraPlus | March 30th – 31st | Paris, France
 PQMD Global Health Policy Forum | April 16th – 18th | Geneva, Switzerland
 US GCSG Conference | April 28th – May 1st | San Antonio, Texas

Tanner Pharma leverages more than 16 years of pharma services experience. The company provides services through four synergistic divisions located in the U.S. and U.K.; TannerCTS, clinical trial services; TannerMAP, managed access programs, TannerLAC, licensing, acquisition and commercialization; and TannerGAP, global access programs.

Our CTS, MAP and Corporate Development teams will be attending these events. Representatives include Graeme Birrell, TannerCTS Business Development Lead, Jonathan Bracey, Managing Director UK – SVP of Corporate Development, and Rob Keel, Director for TannerMAP.

Individuals who wish to schedule a meeting with representatives from Tanner Pharma may contact:

Shona John | sjohn@tannerpharma.com | +44 (0) 20 3940 8117

About Tanner Pharma Group
Tanner Pharma Group is a global service provider in the healthcare industry with a core purpose of improving lives through increased access to medicines. Each of its four service divisions is built on a foundation of a robust distribution network with industry-leading quality standards. Founded in 2003, the company works with a broad range of companies to distribute life-saving medications to patients in more than 120 countries. For more information about Tanner Pharma Group, please visit www.tannerpharma.com.

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

Annapolis, Md. – January 23, 2019 – The Partnership for Quality Medical Donations (PQMD), is proud to announce the addition of Tanner Pharma Group to their membership. The Charlotte, N.C., based global pharmaceutical company becomes the 42^nd member of PQMD.

“Tanner Pharma Group is proud to become a member of PQMD and work alongside other organizations dedicated to the betterment of global healthcare. With our shared commitment to the health and well-being of patients in underserved communities around the world, we look forward to the meaningful and innovative work we will achieve together,” said Banks Bourne, Founder and Chairman of Tanner Pharma Group.

Tanner Pharma Group is a global service provider in the healthcare industry with a core purpose of improving lives through increased access to medicines. Each of its four service divisions is built on a foundation of a robust distribution network with industry-leading quality standards. Founded in 2003, the company works with a broad range of companies to distribute life-saving medications to patients in more than 120 countries.

“PQMD is thrilled to welcome Tanner Pharma Group to what is an increasingly diverse group of international pharmaceutical companies,” says Elizabeth Ashbourne, executive director of PQMD. “Each new member brings with them a unique skillset from which our membership as a whole can learn and grow, and we look forward to their expertise and a successful partnership.”

A global alliance of corporations and NGOs, PQMD leads the development and championing of high standards in medical supply and service donation. The cornerstone of the organization, “PQMD Guidelines for Quality Medical Product Donations,” are a set of guidelines which are rigorously updated on an annual basis to help manage donated medical products, devices and services and the performance of those who participate in the industry worldwide. Seeking to enhance access to healthcare in underserved communities and areas affected by disaster, PQMD members focus their broad expertise in the areas of humanitarian assistance, disaster response, health system strengthening, and knowledge and innovation.

PQMD is a dynamic alliance and global network between nonprofit and corporate organizations leading in the development and championing of guidelines on quality for the donation policies and practices; delivering of urgent care in disaster situations, and delivering life-saving products and service to at-risk and chronically underserved populations. The organization’s beginnings go back to 1996, when an informal alliance of several non-governmental organizations (NGOs), pharmaceutical companies, and medical device firms joined together to develop guidance regarding medical donations. To learn more, visit www.pqmd.org.

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Nephcentric LLC (“Nephcentric”), a developer and marketer of evidence based therapeutic options for people with kidney disease and metabolic disorders. The agreement names Tanner as a distributor of ure-Na (Urea 15g) in areas outside of the United States, Canada, and the Middle East where the product is not yet registered. ure-Na (Urea 15g) is a Medical Food for the management of hyponatremia.

The distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turn key global access solutions for the distribution of products from markets of supply to markets of demand.

Maryori Alvarenga, Managing Director of US and Global Director for TannerGAP, commented, “We are excited to work with Nephcentric on a global level to provide ure-NA access to patients in need.”

Caroline Von Scheven, Operations Lead for Nephcentric, added, “We are looking forward to our partnership with Tanner to help expand our reach beyond North America. Our partnership with Tanner will help more patients in need gain access to our cost-effective, evidence-based therapeutic options”.

To obtain additional details about Global Access Programs, please contact a Tanner Pharma representative at +1 704 552 8408 or email general@tannerpharma.com. For Nephcentric product related enquiries, please email nephcentric@tannerpharma.com.

About Nephcentric LLC:

Nephcentric LLC focuses on cost effective, problem solving, needs-based therapeutic options for patients and physicians. Unlike a traditional biopharmaceutical company, which often relies on higher prices in the specialty space, Nephcentric relies on a lower cost, high efficiency model to bring ure-Na and other products to the medical marketplace. For more information, please visit www.nephcentric.com.

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

CHARLOTTE, N.C. – Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with MannKind Corporation (“MannKind”, NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The agreement names Tanner as a distributor of Afrezza® (insulin human) Inhalation Powder in areas outside of the United States where the product is not yet registered. Afrezza is a rapid-acting, inhaled insulin for Type 1 and Type 2 diabetes.

The ex-U.S. distribution will be managed by TannerGAP, Inc. (“TannerGAP”), a wholly owned subsidiary of Tanner Pharma Group. TannerGAP offers turnkey global access solutions for the distribution of products from markets of supply to markets of demand. The team fields international inquiries and works with physicians, hospitals and ministries of health in underserved areas to provide medicine that is not currently available in their country.

Banks Bourne, Chairman and Founder of Tanner Pharma Group, commented, “TannerGAP’s named patient access program has the proven ability to support product distribution in areas of need. We are pleased to partner with MannKind in helping to fulfill the demand for Afrezza® in countries outside the U.S.”

“With the growing popularity of Afrezza in the U.S., we’re also focusing on bringing the benefits of Afrezza to those with diabetes living in underserved international markets,” said Michael Castagna, Chief Executive Officer at MannKind. “Partnering with Tanner Pharma, which excels in bringing life-changing medicine to underdeveloped countries, will help us reach those goals.”

To obtain additional details about Global Access Programs, please contact a Tanner Pharma representative at +1 704 552 8408 or email general@tannerpharma.com. For MannKind product related enquiries, please email mannkind@tannerpharma.com.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the company’s first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Contact:
Lindsey Stevens
Tanner Pharma Group
704-552-8407
lstevens@tannerpharma.com

SEATTLE, WA – The Max Foundation (“Max”), an international health organization dedicated to serving cancer patients, and Tanner Pharma Group (“Tanner”), a global pharma services company specializing in access to critical medication, are committed partners in bringing thousands of patients around the globe daily access to cancer treatment. Within The Max Foundation’s patient-centered model, Max Access Solutions (MAS), Tanner plays a critical role by leading quality, regulatory and logistics to ensure donated oncology products get to the right patient in the right place at the right time. MAS programs currently deliver 1,000,000 daily doses per Quarter.

Among the dozens of countries The Max Foundation supports, many are located in Africa. To raise awareness and funds for increased treatment access on the continent, Max has created a 2018 campaign known as the Max Global Experience: Uganda.

This campaign is focused on the proverbial “last mile,” which refers to the unseen efforts of patients and caregivers to make treatment truly accessible. All too often, patients must travel great distances to attend medical appointments and receive their medication. Max works to bridge these gaps by broadening its geographic reach, working with local patient groups, advocating to governments, and partnering with distribution experts like Tanner. Tanner has proudly offered to be the title sponsor for the Max Global Experience: Uganda and their parent company, Bourne Partners, will match up to $10,000 in funds raised.

“As we work to find solutions for patients in need, we feel fortunate to partner with a trusted Managed Access Program provider like Tanner Pharma Group,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We are strongly aligned in our values around the importance of access to cancer treatment for people around the world. As a result, we have forged a successful partnership in our Max Access Solution model which provides life-saving medication to patients in more than 70 countries. We look forward to growing our programs with Tanner and improving the lives of more cancer patients in under-resourced countries.”

“We are proud of our affiliation with The Max Foundation and the support we provide for their innovative, globally recognized programs,” added Banks Bourne, Founder & Chairman of Tanner Pharma Group and CEO of Bourne Partners. “Working with Pat and her team is deeply rewarding. Their hard work has led to monumental impact at the patient level.”

In 2017, Mr. Bourne attended another Max Global Experience, this time climbing Mt. Kinabalu in Malaysia. Banks recalls, “Seeing their work in Asia last summer and looking ahead to the upcoming trip to Africa has been inspirational and makes Tanner’s mission even more meaningful.”

About The Max Foundation

The Max Foundation is a global health organization that believes all people living with cancer deserve access to the best treatment, care, and support. The company works to decrease premature mortality from cancer by channeling humanitarian donations of life-saving oncology products to underserved populations in countries where those products are not locally available. For more information, visit www.themaxfoundation.org.

CHARLOTTE, N.C., August 21, 2015 – Tanner Pharma Group will be largely showcased at the upcoming Bourne Partners Fifth Annual Global Healthcare Executive Summit on September 3, in Charlotte, North Carolina.

The conference, held at the internationally renowned Mint Museum, will feature top executives participating in a variety of panel discussions regarding healthcare and pharmaceutical issues and trends, as well as opportunities for attendees to interact one-on-one with industry leaders and innovators.

Conference attendees will include global healthcare and consumer executives from a variety of disciplines, including the pharmaceutical, hospital and healthcare technology sectors; private equity investors; and partners, investors, and clients of Bourne Partners and Tanner Pharma Group.

Joshua Cooper, Director of Corporate Development, will lead the Healthcare Services Panel, “Changing Dynamics of Pharma Services.”  Below is a representative list of panellists participating in the discussion:

David W. Bryant, Chairman and CEO of SeLux Diagnostics, Inc.

David Crane, Chairman and CEO of National Surgical Healthcare

Derek Hennecke, CEO and President of Xcelience

Michael Kane, CEO and Founder of Agilem Strategy, LLC.

“The panel is a great opportunity to showcase thought leaders in the healthcare services space and discuss opportunities in this rapidly evolving sector” said Mr. Cooper.

Tanner Pharma Group will also present a corporate overview highlighting recent hyper-growth and global expansion.

The two-day event is hosted by Bourne Partners, a leading healthcare and consumer-healthcare investment banking, merchant banking, and investment firm.

The fifth annual Bourne Partners Global Healthcare Executive Summit, featuring guest speaker, Jeff Gordon, a four-time NASCAR Series champion and presenters from leading pharmaceutical, pharma services, specialty pharma, biotech companies and investors, will take place Sept. 2-3 in Charlotte, N.C.

For additional information about Bourne Partners or the Bourne Partners Global Healthcare Executive Summit, please contact your Bourne Partners representative or Kristi Orange at 704-714-8367 or korange@bourne-partners.com.

CHARLOTTE, N.C. – Top executives from Tanner Pharma Group will speak at the largest life-science conference in the world, the 2015 BIO International Convention, scheduled for June 15-18 in Philadelphia. The presentations will provide key insights into enhancing product access and commercialization for pharmaceutical companies in challenging international markets.

On June 16, Carolina Cortez, Director of Tanner Pharma Group’s Licensing, Acquisition and Commercialisation Division (TannerLAC), will present “Overcoming Challenges in the Evolving Latin American Market.” Cortez’s presentation will address the complexities of penetrating the Latin American market through registration and promotion, and discuss solutions to commercializing pharmaceutical, biotech and healthcare products including partnering, licensing and targeted divestitures.

Then on June 17, Joshua Cooper, Director of Corporate Development for Tanner Pharma Group, will present “Enhancing Access; Minimizing Investment.” Cooper will share alternative strategies to unlocking value in lower priority markets where pharmaceutical firms often see demand for products.

With over 12 years of international pharmaceutical experience, as well as fluency in English, Spanish and Portuguese, Cortez has a proven ability to drive value in international markets. Under her leadership, TannerLAC provides pharmaceutical, biotech and healthcare companies with access to emerging markets while minimizing the risk, investment and resources necessary for companies to register, market and maximize sales in Latin America and other international markets.

Previously a member of the Bourne Partners investment banking team, Cooper combines his financial background with his global pharmaceutical commercial experience at Merck Sharpe & Dohme, Novartis, and Valeant. He oversees key strategic and commercial initiatives at Tanner as well as Global Access Programmes, including Named Patient Programmes, Expanded Access Programmes, Compassionate Use Programmes, and Emergency Supply allocations.

Both Tanner Pharma Group presentations will take place at 10 a.m. in the Exhibit Hall at the North Carolina Pavilion, booth 4235. Each 20-minute session will be followed by a 10-minute question and answer period. For more information, feel free to contact CCortez@TannerPharma.com or JCooper@TannerPharma.com directly. Both contacts will also be available for meetings through the BIO One-on-One PartneringTM system.

Tanner Pharma Group, a global provider of integrated specialty access solutions, announces the signing of an exclusive distribution agreement with Merz North America, a specialty healthcare company with a strong commitment to the U.S. neurosciences space. The agreement names Tanner Pharma Group as Merz North America’s sole Named Patient distributor of Cuvposa^® (glycopyrrolate) oral solution in Latin America where Cuvposa^® (glycopyrrolate) oral solution is not yet registered.

“We have customized a Named Patient Program for Merz North America whereby we will fulfill requests for Cuvposa^®(glycopyrrolate) oral solution by healthcare providers in Latin America who seek to incorporate this product into their treatment regimens for pediatric neurology patients,” stated Maryori Alvarenga, Managing Director of Tanner Pharma Group. “Many patients between the ages of 3 and 16 experience problem drooling due to certain neurological diseases including cerebral palsy. By providing a controlled, regulatory-compliant channel of distribution directly to the provider, patients in any market can benefit from advancements made in the larger markets of the US, Europe and Canada.”

“Here at Merz North America, we believe that Cuvposa^® (glycopyrrolate) oral solution provides a clear improvement to quality of life for pediatric patients suffering from sialorrhea who otherwise might rely on non-pharmaceutical treatments including surgery, or simply go without treatment,” said Glenn Block, Vice President and Head – U.S. Neurosciences for Merz North America.. “We are excited to enter this collaboration with Tanner Pharma Group to provide this important treatment to pediatric neurology patients in Latin America.”

Over the last two years, Tanner Pharma Group has experienced transformational growth as the company has quickly become a leading provider of Global Access Programs in Latin America, Europe and more recently Asia and the Middle East. The company’s Clinical Trials Division has grown to provide comparator sourcing to manufacturers and contract research organizations (CROs) around the world and logistics services for trials in the U.S., Europe, Mexico and Brazil. Tanner Pharma Group’s world class team of Client Support Representatives, Regulatory Administrators and Legal Affairs personnel have come together to provide more comprehensive solutions to upstream partners including big pharma, specialty pharma, biotech and consumer/OTC companies, as well as to downstream providers including governments, hospitals, clinics, pharmacies, and physicians.

About Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of Merz products has been based on our commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer’s disease research. Founded in 1908, Merz Pharma Group is a privately-owned company headquartered in Frankfurt, Germany.

For more information about Merz or the Company’s products, please visit www.merzusa.com.